Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.

Lévy, V; Porcher, R; Leblond, V; Fermand, J P; Cazin, B; Maloisel, F; Harousseau, J L; Remenieras, L; Guibon, O; Chevret, S

Lévy, V; Porcher, R; Leblond, V; Fermand, J P; Cazin, B; Maloisel, F; Harousseau, J L; Remenieras, L; Guibon, O; Chevret, S.

Affiliation

Lévy V; Département de Biostatistique et Informatique Médicale, Hjpital Saint Louis, Paris, France.

Leukemia ; 15(9): 1466-70, 2001 Sep.

Article in En | MEDLINE | ID: mdl-11516109

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Cyclophosphamide/therapeutic use; Doxorubicin/therapeutic use; Prednisone/therapeutic use; Quality of Life; Vidarabine/therapeutic use; Waldenstrom Macroglobulinemia/drug therapy; Disease Progression; Health Status Indicators; Humans; Retrospective Studies; Survival Rate; Vidarabine/analogs & derivatives

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Vidarabine / Prednisone / Antineoplastic Combined Chemotherapy Protocols / Doxorubicin / Waldenstrom Macroglobulinemia / Cyclophosphamide Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2001 Type: Article Affiliation country: France

Search on Google

XML

PubMed Links